Latest news with #BantamPharmaceutical
Yahoo
22-05-2025
- Business
- Yahoo
Bantam Pharmaceutical to Present at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
RESEARCH TRIANGLE PARK, N.C., May 22, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its Trial in Progress abstract has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, which is being held May 30 – June 3, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster will highlight the company's ongoing Phase 1 trial evaluating its lead product candidate, BTM-3566, in patients with relapsed/refractory mature B-cell lymphomas. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets difficult-to-treat, aggressive tumors by activating OMA1-ATF4 Integrated Stress Response (ISR), a newly described mitochondrial homeostasis pathway. The Phase 1 multicenter, prospective, dose-escalation study is focused on enrolling patients in the United States and Canada, with the first U.S. site activated at The University of Texas MD Anderson Cancer Center. "Patients with relapsed or refractory B-cell lymphomas continue to face significant clinical challenges, particularly those who have progressed following cell therapy or targeted agents," said Dr. Michael Wang, global principal investigator and professor of lymphoma & myeloma at The University of Texas MD Anderson Cancer Center. "The opportunity to investigate BTM-3566 and its novel mechanism of action is especially compelling given its preclinical activity across diverse hematologic tumor models, including those with high-risk features. Advancing BTM-3566 into the clinic represents an important step toward expanding therapeutic options for patients who urgently need more effective treatments." In the U.S., the study follows a standard 3+3 dose escalation design beginning at 0.3 mg/kg, while the Canadian sub-protocol initiates at 0.9 mg/kg using a single-patient cohort with accelerated dose titration. In both regions, patients receive BTM-3566 orally on Days 1 through 7 of a 14-day cycle. The complementary-dual-country approach accelerates the identification of clinically active doses for lymphoma patients while preserving the scientific rigor required to ensure meaningful clinical impact. It is expected to support future harmonization of U.S. and Canadian data to generate a robust, integrated dataset and inform development strategy. Primary endpoints are safety and tolerability. Secondary and exploratory endpoints include objective response rate (ORR) by revised Lugano criteria, duration of response (DoR), progression-free survival (PFS), and pharmacokinetic and pharmacodynamic assessments. Initial clinical data from the trial are expected in the second half of 2025. While the current trial is focused on treating lymphomas through activating the OMA1-ATF4 ISR, the mechanism represents a broader therapeutic opportunity. Recent preclinical findings have shown that BTM-3566 drives significant regressions in biomarker-selected solid tumors – particularly in difficult-to-treat tumor types. Additionally, combination data demonstrate synergy with standard-of-care agents in acute myeloid leukemia, underscoring the broad potential of this mechanism across both hematological and solid tumors. The company intends to advance these findings clinically as product development progresses. Poster Presentation Details Title: A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomasPresenter: Michael Wang, MD, Department of Lymphoma & Myeloma, MD Anderson Cancer CenterSession: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic LeukemiaDate/Time: Sunday, June 1st at 10 a.m. to 1 p.m. ETAbstract Number: TPS7097 Additional meeting information can be found on the ASCO website, The poster presentation will be made available under the News & Resources section of the company's website shortly after the event. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). Notably, its anti-tumor activity is independent of tumor genotype, addressing a critical need for therapies capable of delivering robust and durable responses across genetically diverse cancers. With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development, broadening its potential impact for patients with limited treatment options. Currently, Bantam is conducting ongoing Phase 1 clinical trials in both the U.S. and Canada evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas. For more information about the U.S. trial, visit and search NCT06792734. For more information about the Canadian trial, visit and search ISRCTN15438979. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at Media Contact Jennifer AlmondCorporate Communications Bantam Pharmaceuticaljalmond@ View original content to download multimedia: SOURCE Bantam Pharmaceutical, LLC
Yahoo
25-04-2025
- Business
- Yahoo
Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American Association for Cancer Research (AACR) Annual Meeting 2025
• BTM-3566 shows solid tumor regression and identifies FAM210B as a potential biomarker for response and combination strategies RESEARCH TRIANGLE PARK, N.C., April 25, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced solid tumor regression data from Bantam's lead product candidate, BTM-3566. These preclinical data will be shared in a poster presentation during the American Association for Cancer Research (AACR) Annual Meeting, being held from April 25-30, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster highlights evidence of robust anti-tumor activity in a broad range of solid tumor models, as well as introduces FAM210B, a mitochondrial protein, as a potential biomarker for response. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets difficult-to-treat, aggressive tumors by activating OMA1-ATF4 Integrated Stress Response (ISR), a newly described mitochondrial homeostasis pathway. Previously, BTM-3566 was shown to have strong single-agent activity in both cell line and patient-derived xenograft (PDX) models of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), regardless of cell of origin (COO) or genotype. The new data extend these findings to solid tumors and demonstrate that BTM-3566 has in vitro and in vivo activity across tumor types. Key findings include: BTM-3566 exhibits in vitro and in vivo activity in a broad range of solid tumor models BTM-3566 drives tumor regression in models with low FAM210B RNA expression, supporting the use of FAM210B as a potential biomarker for response Ectopic expression of FAM210B blocks drug activity in multiple models, suggesting a mechanistic role for the protein in mediating response BTM-3566 demonstrates additive and synergistic activity in combination with other agents from multiple classes in preclinical models, including BH3 mimetics, supporting future combination strategies "These findings provide important insight into the unique mechanism of our lead compound and support the potential for future patient selection using FAM210B expression," said Michael Stocum, President & CEO of Bantam Pharmaceutical. "We believe BTM-3566 holds promise not only as a monotherapy but also in combination with numerous approved anti-cancer agents, potentially expanding treatment options for patients with aggressive, hard-to-treat tumors. We intend to further explore these relationships as product development progresses." Poster Presentation Details Title: Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210BPresenter: Matthew Kostura, PhD, Chief Scientific Officer, Bantam PharmaceuticalSession: Experimental and Molecular TherapeuticsDate/Time: Monday, April 28th at 3 p.m. to 6 p.m. ETAbstract Number: 3032 The poster presentation will be available under the News & Resources section of the company's website shortly after the event. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options. Currently, Bantam is conducting an ongoing Phase 1 clinical trial in both the U.S. and Canada evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas. For more information about the U.S. trial, visit and search NCT06792734. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at Media Contact Jennifer AlmondCorporate CommunicationsBantam Pharmaceuticaljalmond@ View original content to download multimedia: SOURCE Bantam Pharmaceutical, LLC Sign in to access your portfolio
Associated Press
26-03-2025
- Business
- Associated Press
Bantam Pharmaceutical to Present at the American Association for Cancer Research (AACR) Annual Meeting 2025
RESEARCH TRIANGLE PARK, N.C., March 26, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its abstract has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 25-30, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster presentation will highlight solid tumor regression data from Bantam's lead product candidate, BTM-3566. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets difficult-to-treat aggressive tumors by activating the OMA1-ATF4 Integrated Stress Response (ISR), a newly described mitochondrial homeostasis pathway. Leveraging its unique mechanism of action, BTM-3566 demonstrated robust activity as a single agent in vivo in solid tumors with low FAM210B RNA expression. Additionally, preclinical data suggest that rational combinations with BH3 mimetics could extend the therapeutic potential of BTM-3566, particularly in difficult-to-treat tumors. Poster Presentation Details Title: Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210B Presenter: Matthew Kostura, PhD, Chief Scientific Officer, Bantam Pharmaceutical Session: Experimental and Molecular Therapeutics Date/Time: Monday, April 28th at 3 p.m. to 6 p.m. ET Abstract Number: 3032 Additional meeting information can be found on the AACR website, The poster presentation will be made available under the News & Resources section of the company's website shortly after the event. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options. Currently, Bantam is conducting an ongoing Phase 1 clinical trial in both the U.S. and Canada evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas. For more information about the U.S. trial, visit and search NCT06792734. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at Media Contact Jennifer Almond
